CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
Sponsors
University of Washington
Conditions
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8
Phase 1
Phase 2
A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
RecruitingNCT05242965
Start: 2023-03-24End: 2032-11-21Target: 40Updated: 2026-07-27
STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
Active, not recruitingNCT05455658
Start: 2022-11-17End: 2028-07-16Updated: 2026-07-23
A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
RecruitingNCT07078604
Start: 2026-03-24End: 2028-06-30Target: 20Updated: 2026-08-04
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
RecruitingNCT07112053
Start: 2025-11-17End: 2028-12-31Target: 40Updated: 2026-04-06
A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden
Not yet recruitingNCT07721259
Start: 2026-09-30End: 2030-07-16Target: 60Updated: 2026-07-23